【24h】

RLIP76: a target for kidney cancer therapy.

机译:RLIP76:肾癌治疗的靶标。

获取原文
获取原文并翻译 | 示例
           

摘要

RLIP76 is a multifunctional transporter protein that serves as an energy-dependent efflux mechanism for endogenously generated toxic metabolites as well as exogenous toxins, including chemotherapy drugs. Our recent studies in cultured cells, syngeneic animal tumor model, and in xenograft model have shown that RLIP76 serves a major cancer-specific antiapoptotic role in a wide variety of histologic types of cancer, including leukemia, melanoma, colon, lung, prostate, and ovarian cancer. Results of present studies in cell culture and xenograft model of Caki-2 cells show that RLIP76 is an important anticancer for kidney cancer because inhibition of RLIP76 function by antibody or its depletion by small interfering RNA or antisense DNA caused marked and sustained regression of established human kidney xenografts of Caki-2 cells in nude mouse.
机译:RLIP76是一种多功能转运蛋白,可作为能量依赖性外排机制,用于内源性产生的毒性代谢产物以及包括化疗药物在内的外源性毒素。我们最近在培养细胞,同系动物肿瘤模型和异种移植模型中进行的研究表明,RLIP76在多种组织学类型的癌症(包括白血病,黑素瘤,结肠癌,肺癌,前列腺癌和卵巢癌。目前在Caki-2细胞的细胞培养和异种移植模型中进行的研究结果表明,RLIP76是一种重要的抗肾癌药物,因为抗体对RLIP76功能的抑制作用或小分子干扰RNA或反义DNA的消耗会导致已建立的人类显着且持续的退化裸鼠中Caki-2细胞的肾脏异种移植。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号